How can treatment be individualised by using genomic classifiers? Felix Feng Advanced Prostate Cancer Consensus Conference UroToday.com European Association of Urology (EAU) #APCCC22 #PrecisionMedicine #decipher OncoAlert

PSMA pelvic recurrences: preference for local radiation therapy #APCCC22

"Modern imaging is here to stay. We can now better select treatment. Lead time bias: doesn't matter if treatment is going to be needed. A rationale person would treat as high volume disease" Ian Davis (Bluesky @profiand) Advanced Prostate Cancer Consensus Conference

Debate at #apccc22: Karim FIZAZI & Ian Davis (Bluesky @profiand) on treatment of low volume #prostatecancer pts by conventional but high volume by next generation imaging. Treat like LV or HV? Q: is dichotomization the best way to measure tumor burden? Should we not develop a continuous measure?

Learning points: Mean SUV cutoff of 10 predictive of 177Lu-PSMA-617 response with mCRPC, 177Lu-PSMA-617 improves Progression free and overall survival. Further improvement of responses with combination therapies of PSMA RLT and other agents to be investigated Advanced Prostate Cancer Consensus Conference

The frontiers of molecular imaging in early #mCRPC to drive appropriate tracers and understand biological changes of #prostatecancer #APCCC22

When low-volume on conventional imaging goes into high-volume on next-generation imaging in #mHSPC - Treat like high-volume. Presentation by Ian Davis (Bluesky @profiand) Monash University. #APCCC22 written coverage by Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/3vJMo0A Advanced Prostate Cancer Consensus Conference

Interested in focal saturation biopsy to overcome stage migration?doi.org/10.1016/j.euro… Gianluca Giannarini Caroline Moore Declan Murphy Hashim U. Ahmed Ivo Schoots Baris Turkbey MD Andrew Vickers

Pitfalls and Controversial Cases with PSMA PET CT. prof. Stefano Fanti, Christopher Sweeney, MBBS Dana-Farber, Neal Shore, MD, FACS AtlanticUroClinics discuss what to do when you have bone findings at PSMA PET with no CT counterpart > bit.ly/3ghfvEE @adacap_news @PointBiopharma

#PSMA PET/CT may be predictive of treatment response in patients with mCRPC, regardless of ongoing systemic therapy. Response assessed by #PETCT is a potentially more significant prognostic factor than PSA for PFS. ow.ly/bIwj50Muquz #NuclearMedicine prof. Stefano Fanti

1/ #LuTectomy #EAU23 Game Changing Session: first use of Lu-177 PSMA-617 first-line in patients with high-risk localised N0/N1 prostate cancer: 20pt. 1-2 cycles→prostatectomy. ☢36Gy. 45% PSA50-RR. Safe. Few toxicities. Renu Eapen Declan Murphy European Association of Urology (EAU)

#LuTectomy A prospective study of dosimetry, safety, and potential benefit of upfront 177Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR localized #ProstateCancer. Presented by Renu Eapen Peter Mac Cancer Centre. #EAU23 Zach Klaassen > bit.ly/429A0qn

🏆YES! the patient went under partial nephrectomy and it was pRCC! And about the 2 question, there are some features we can't miss in the characterisation of renal mass, but, if you want to give your reports some⭐️QUALITY⭐️you can add those scores. Urologists will be thankful.

Introducing our new Diagnostic and Interventional Radiology residents! We are so thrilled to have you! Congratulations and welcome to the family!! 🎉 UTHealthRadRes UT Houston_IR McGovern Med School #Match2023 #MatchDay #radres #futureradres

🌟Introducing PROMISE 2 for standardized evaluation of PSMA PET/CT! 📄Unlock the full potential for clinical routine & research 🔍🎯 Improve accuracy & consistency💪 #PSMA authors.elsevier.com/sd/article/S03… European Association of Urology (EAU)

PROMISE V2 pocket card

Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis pubs.rsna.org/doi/10.1148/ra… 🔵Nice systematic review from 🇩🇪 #prostatecancer #prostateMRI #cancerresearch

Oerther et al performed a systematic meta-analysis of diagnostic accuracy of the PI-RADS version 2.1 categories in this Editor's Choice article, finding 96% sensitivity for clinically significant prostate cancer in PI-RADS scores greater than or equal to 3 bit.ly/4dFEjyC

In this targeted editorial, Drs. Sairam Tammisetti and Jacobs discuss the implications of the study by Oerther et al and future directions for artificial intelligence in prostate cancer detection. bit.ly/3yITTKR

The Magician's Corner: Learn #AI in radiology by doing! pubs.rsna.org/page/ai/magici… #MachineLearning #Radiomics #ArtificialIntelligence